AlphAIalphai — Financial news for AI agents
TradingViewAPR 301 min read$AKTX

Debt to equity ratio of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1

This page provides the debt to equity ratio for Akari Therapeutics Plc Sponsored ADR, traded under the symbol CLA1 on the Munich Stock Exchange. It is part of a financial overview for the company, accessible through TradingView. The content primarily displays the financial metric without further descriptive analysis or historical data on this specific page.

Original reporting
TradingView
Published Apr 30, 2026, 5:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 30, 2026, 7:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Debt to equity ratio of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 — source image
Source · TradingView
Decision brief

The 30-second read

$AKTXNeutralLow
01

Why it matters

The ratio alone does not significantly influence trading decisions without additional context.

02

Market read

Low relevance for immediate trading decisions; more data needed for strategic analysis.

03

What to watch

Other financial metrics such as debt maturity profile, cash flow, and overall profitability are necessary for a comprehensive assessment.

Timing: Not time-sensitive

Background

This page presents the debt-to-equity ratio for Akari Therapeutics Plc (CLA1), traded on the Munich Stock Exchange, as part of a broader financial overview.

Company-level read

Ticker impact

$AKTXNeutralMedium confidence
Context

Low relevance due to minimal impact on broader markets

Expected impact

No significant immediate price movement expected

Evidence & confidence

The ratio alone provides limited insight; comprehensive analysis requires more financial data.

Market effects

Sector

Limited sector impact; financial ratios are specific to individual companies

Regional

Minimal regional influence

Global

Low relevance to global markets

Counterpoint

What could challenge this read

While the ratio appears moderate, some investors might interpret it as a sign of manageable leverage, supporting a cautious long-term position.

Key entities

  • Company
    Akari Therapeutics Plc

    A biopharmaceutical company focused on immune-mediated diseases.

Read at source← All news

Related articles

MAY 30
$AKTXMed

Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics (NASDAQ:AKTX) saw short interest rise to 64,685 shares as of May 15, up from 16,135 on April 30, with about 8.2% of shares sold short and a short-interest ratio of 1.8 days. Armistice Capital bought 2,723,966 shares in Q4, valuing the stake at ~$787,000 (5.95%). Analysts’ consensus is “Hold” with a $89 target. The stock traded at $16.43; EPS missed on May 20.

dailypolitical.com4 min
MAY 29
$SPRCMedAI 8/10

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

rttnews.com6 min
AUG 8
$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

fool.com6 min
AUG 8
$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min
AUG 8
$APLDMedAI 8/10

APLD Stock Rallies After Hours On Massive New $7.5 Billion Hyperscaler Lease: Retail Think Firm Should Be Worth More Than Rival IREN

Applied Digital (APLD) shares rose more than 7% after hours after the company said it surpassed 1 GW of contracted capacity for its AI data centers. It signed a 15-year take-or-pay lease for Polaris Forge 3 with a U.S. investment-grade hyperscaler, valued at about $7.5B base-term contracted revenue and up to $18.2B with renewals. Total contracted lease revenue across four campuses is $31B.

stocktwits.com4 min